Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort

被引：31

作者：

Wallis, Dinny ^{[1
]}

Thavaneswaran, Arane ^{[1
]}

Haroon, Nigil ^{[1
]}

Ayearst, Renise ^{[1
]}

Inman, Robert D. ^{[1
]}

机构：

[1] Univ Toronto, Toronto Western Hosp, Div Rheumatol, Toronto, ON M5S 1A1, Canada

来源：

RHEUMATOLOGY | 2015年 / 54卷 / 01期

关键词：

axial spondyloarthritis; ankylosing spondylitis; infection; biologic; SOCIETY CLASSIFICATION CRITERIA; FACTOR-ALPHA ANTAGONISTS; RHEUMATOID-ARTHRITIS; ANKYLOSING-SPONDYLITIS; SERIOUS INFECTIONS; HOSPITALIZATION; METHOTREXATE; TRIALS;

D O I：

10.1093/rheumatology/keu255

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Methods. Data were extracted from a longitudinal observational cohort of patients with axSpA. Infection rates were calculated and multivariate analysis was performed to investigate the association of independent variables with infection. Results. Data were analysed for 440 patients followed for a total of 1712 patient-years (pys). A total of 259 infections, of which 23 were serious, were recorded in 185 patients. The overall rate of any infection was 15 (95% CI 13, 17)/100 pys and the serious infection rate was 1.3 (95% CI 0.9, 2.0)/100 pys. There was no significant difference in the rate of any infection or serious infection in patients on TNFis compared with patients never on biologic agents. In the multivariate analysis, DMARD treatment, but not TNFi treatment, was associated with risk of infection. Age, disease duration, smoking status, BASFI, BASDAI, co-morbidity score and hospitalization were not associated with an increased risk of infection. Conclusion. The serious infection rate in axSpA in this observational cohort is low when compared with rates reported in other rheumatic diseases. Biologic use was not a significant risk factor for serious infection.

引用

页码：152 / 156

页数：5

共 13 条

[11] The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal [J].

Rudwaleit, M. ;

Landewe, R. ;

van der Heijde, D. ;

Listing, J. ;

Brandt, J. ;

Braun, J. ;

Burgos-Vargas, R. ;

Collantes-Estevez, E. ;

Davis, J. ;

Dijkmans, B. ;

Dougados, M. ;

Emery, P. ;

van der Horst-Bruinsma, I. E. ;

Inman, R. ;

Khan, M. A. ;

Leirisalo-Repo, M. ;

van der Linden, S. ;

Maksymowych, W. P. ;

Mielants, H. ;

Olivieri, I. ;

Sturrock, R. ;

de Vlam, K. ;

Sieper, J. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) :770-776

[12] The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection [J].

Rudwaleit, M. ;

van der Heijde, D. ;

Landewe, R. ;

Listing, J. ;

Akkoc, N. ;

Brandt, J. ;

Braun, J. ;

Chou, C. T. ;

Collantes-Estevez, E. ;

Dougados, M. ;

Huang, F. ;

Gu, J. ;

Khan, M. A. ;

Kirazli, Y. ;

Maksymowych, W. P. ;

Mielants, H. ;

Sorensen, I. J. ;

Ozgocmen, S. ;

Roussou, E. ;

Valle-Onate, R. ;

Weber, U. ;

Wei, J. ;

Sieper, J. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) :777-783

[13] INFECTION-RATE AND USE OF ANTIBIOTICS IN PATIENTS WITH RHEUMATOID-ARTHRITIS TREATED WITH METHOTREXATE [J].

VANDERVEEN, MJ ;

VANDERHEIDE, A ;

KRUIZE, AA ;

BIJLSMA, JWJ .

ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (04) :224-228

← 1 2 →